Brian King
@briankingneo.bsky.social
310 followers 60 following 55 posts
Neo at BIDMC and Harvard Med. Interests are neoEBM and health economics. SoMe lead EBNEO. NeoTECAN Early Career & Journal Club Exec . He/Him. Opinions my own.
Posts Media Videos Starter Packs
briankingneo.bsky.social
Our next webinar is on April 3rd, at 4:00 pm EST! Register here - uab.zoom.us/meeting/regist…
Dr. Gomez Zaghmout (Neonatal-Perinatal Fellow, University of Miami) will present the PPaX Trial, a cluster randomized trial of xylitol chewing gum in Malawi to prevent preterm birth.
Note: Since your browser does not support JavaScript, you must press the Continue button once to proceed.
https://uab.zoom.us/meeting/regist…
briankingneo.bsky.social
The most recent AAP SONPM Journal Club webinar is available - youtu.be/beh82Mgor7Q
Dr. Aung (Neonatal-Perinatal Fellow, St. Christopher's Hospital) gave an excellent overview of the PLUSS trial. Thank you to @drbretty.bsky.social and Dr. Watterberg for joining! #neobluesky
AAP SONPM Journal Club - March 19th, 2025 - PLUSS Trial
YouTube video by Neo TECaN
youtu.be
briankingneo.bsky.social
Thank you.

Particularly when choosing to share it already. If you want to keep it until publication, don't submit it to the largest pediatric conference in the USA (or world?).

At that point, the only group that benefits from not sharing it further is the conference.
briankingneo.bsky.social
I'm certainly no nutrition expert so defer to you and others - but surely length is still ultimately a surrogate short term outcome?

At 2 years, or 5 years is our "primary outcome" (concern) the baby's height? Or how that growth impacted brain development (and subsequently neurodevelopment)?
briankingneo.bsky.social
Join us for our next Journal Club, next Wednesday (March 19th) at 6:00 pm EST - uab.zoom.us/meeting/regist…
Neonatal-Perinatal Fellow Htay Aung, MD will review the Pluss Trial joined by Dr. Brett Manley and Dr. Kristi Watterberg#neoblueskyky
briankingneo.bsky.social
If you missed it, check out the latest AAP Neonatal Journal Club - youtu.be/0_iqc78Fh5c
@arichaimd.bsky.social provided an excellent review of the BeNeDuctus Trial, with great learning points by Tim Hundscheid and @jslaughtermd.bsky.social #neobluesky #neoEBM
AAP SONPM Journal Club - February 27, 2025 - BeNeDuctus Trial
YouTube video by Neo TECaN
youtu.be
Reposted by Brian King
ebneo.bsky.social
A large cohort study @WHOBulletin suggests no evidence of increased risk of BPD following birth dose hepatitis b vaccination in preterm infants buff.ly/rRPi3Gl

#neobluesky #neoEBM #EBNEOalerts
briankingneo.bsky.social
If your work is meaningful, it will still be shared. Human nature. It will be "word of mouth". I think we all know how well that goes.

Sharing actual content (poster, slides) allows your views on the work to be heard more accurately.
briankingneo.bsky.social
You're already sharing your work, potentially to several hundred. They have all paid for access (and you've paid for the privilege).

Many can't because of the funds required (Hawaii is expensive!) or simply because they are doing the important work back home (patient care).
briankingneo.bsky.social
As you start to think about presenting your work #PAS2025, this is another year where the decision to share is delegated to you.

Think about who research is for (patients, families, all clinicians). Gatekeeping access is counterproductive #neobluesky #neosky #neoEBM
briankingneo.bsky.social
#neobluesky #neosky

I've noticed when tagging accounts the list that comes up in a post is noticeably worse than some other platforms and finding who I want. It appears there is little preference to those I follow.

Anyone found any settings that change this?
briankingneo.bsky.social
Excited for the first AAP SONPM Journal Club Webinar tomorrow at 3:00 pm EST. @arichaimd.bsky.social will present the Beneductus Trial, with Tim Hundscheid and Jon Slaughter joining as mentors. Register here shorturl.at/w7lZf #neobluesky @ebneo.bsky.social #neoEBM
briankingneo.bsky.social
Preterm cooling trial published, previously presented at PAS 2023.

No difference in primary outcome. Bayesian analysis suggests 87% probability of increased risk of death with hypothermia. Practice changing for those who are cooling this population?

#neobluesky

jamanetwork.com/journals/jam...
Whole-Body Hypothermia for Neonatal Encephalopathy
This randomized clinical trial investigates if hypothermia initiated at less than 6 hours after birth reduces the probability of death or disability at 18 to 22 months’ corrected age in infants 33 to ...
jamanetwork.com
briankingneo.bsky.social
Validation is done within the same dataset - that's obviously important, but external validation more so especially given such wide variation in PDA practices.

Lastly - predicting an outcome doesn't mean we can change the outcome. Would want to show that acting on the score prevents surgery.
briankingneo.bsky.social
Difficult to find the enrollment period in this paper - found it by downloading the original cohort paper (2015-2016).

Is this PDA surgery, or device closure? If actually surgery, it doesn't reflect practice in most places IMO. I've not seen a surgical closure in ~6 years.
briankingneo.bsky.social
Looks like Bluesky also doesn't have an edit feature.
briankingneo.bsky.social
I'm Vienna it sounded like it maybe wasn't going to be ready by PAS. I haven't looked through the program yet.
briankingneo.bsky.social
FEED1 trial should be presented this year I think, which will hopefully provide compelling confirmatory data of this practice in a much larger trial.
briankingneo.bsky.social
Yes that's totally reasonable. Look forward to the larger cohort.
briankingneo.bsky.social
Thanks!
Multivariable analysis will be helpful in a larger cohort (how much does the GA diff account for the score diff?)

Could also include measures of prediction (AUC, Sens/Spec). Assume you used the same score cut off as in previous papers. Could a different cut off predict AKI better?
briankingneo.bsky.social
Thanks for sharing!

It says the score was calculated on DOL2 but none received PDA treatment until >7 days - is that your standard practice? Or is this excluding those who met your treatment criteria before 7 days?
briankingneo.bsky.social
Thanks for sharing! Looking forward to reading!

I often think about what society is willing to invest at the beginning of life, compared to what we invest on the aging generation. Not saying we shouldn't do both, but Pediatric/Neonatal care offers an incredible "return on investment".